Company: TAK
Filing Date: 2025-06-26
Form Type: 424B5
Source: 0001395064-25-000101
Chunk: 7

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-26
Form: 424B5
Chunk 7
---
 reference. See “Where You Can Find More Information—Incorporation by Reference” for a list of documents being incorporated by reference herein.

The terms “yen” or “¥” refer to Japanese yen, “$” refers to U.S. dollars and “EUR” or “€” refer to Euros, respectively. In this prospectus supplement and the accompanying prospectus, yen figures and percentages have been rounded to the figures shown, unless otherwise specified. In tables and graphs with rounded figures, sums may not add up due to rounding.

Takeda’s fiscal year end is March 31. References to years not specified as being fiscal years are to calendar years. In this prospectus supplement, all of Takeda’s financial information is presented on a consolidated basis, unless we state otherwise.

<div align='center'>S-v</div>

### PROSPECTUS SUPPLEMENT SUMMARY
This summary highlights key information described in greater detail elsewhere, or incorporated by reference, in this prospectus supplement and the accompanying prospectus. You should read carefully the entire prospectus supplement, the accompanying prospectus and the documents incorporated by reference before making an investment decision.

### TAKEDA PHARMACEUTICAL COMPANY LIMITED
TPC is a joint stock corporation incorporated under the laws of Japan and the Guarantor of the Notes. TPC is the parent company of the Takeda group, a global, values-based, R&D-driven biopharmaceutical company with a diverse portfolio, engaged primarily in the research, development, production and global commercialization of pharmaceutical products. Takeda’s business is grouped into six key business areas: Gastroenterology, Rare Diseases, Plasma-Derived Therapies (“PDT”), Oncology, Vaccines and Neuroscience. Our R&D efforts are focused on three core therapeutic areas: Gastrointestinal and Inflammation, Neuroscience and Oncology. We also make targeted R&D investments in PDT. We focus on developing innovative medicines that make a difference in people’s lives by advancing the frontier of new treatment options and leveraging our collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. We focus on high unmet medical needs, both in rare and more prevalent conditions, to deliver high-quality medicines to patients and communities as quickly as possible. We have a presence in approximately 80 countries and regions, a network of manufacturing sites around the world, primarily in the United States, Europe, Japan, and Singapore and major research centers in Japan and the United States. Commercially,